Mineralys Therapeutics, Inc. Common Stock • MLYS

Capital at risk.

About Mineralys Therapeutics, Inc. Common Stock
Ticker
info
MLYS
Trading on
info
NASDAQ
ISIN
info
US6031701013
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Jon Congleton
Headquarters
info
150 N. Radnor Chester Rd., Radnor, PA, United States, 19087
Employees
info
51
Website
info
https://mineralystx.com
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Metrics
BasicAdvanced
Market cap
info
$3.51B
P/E ratio
info
-
EPS
info
-$2.92
Dividend Yield
info
0.00%
Beta
info
0.4
Forward P/E ratio
info
0
EBIDTA
info
$-184M
Ex dividend date
info
-
Price & volume
Market cap
info
$3.51B
Average daily volume
info
1.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
6.08
Earnings
EPS
info
-$2.92
EPS estimate (current quarter)
info
-$0.61
EPS estimate (next quarter)
info
-$0.59
EBITDA
info
$-184M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.4
52-week High
info
$47.65
52-week Low
info
$8.24
50-day moving average
info
$39.83
200-day moving average
info
$20.34
Short ratio
info
6.29
Short %
info
10.85%
Management effectiveness
ROE (TTM)
info
-42.14%
ROA (TTM)
info
-26.51%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
79.1M
Float
info
55.1M
Insiders %
info
1.74%
Institutions %
info
97.12%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

info
$45.75
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.98
-$1.08
9.26%
Q4 • 24Beat
-$0.79
-$0.98
19.39%
Q1 • 25Beat
-$0.66
-$0.74
10.81%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-43.3M
-∞%
Q2 • 25
$0M
$-36.9M
-∞%
Q3 • 25
NaN%
-14.66%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$336M
$22.2M
6.60%
Q2 • 25
$600M
$23.5M
3.92%
Q3 • 25
78.70%
6.07%
-40.64%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-30.2M
$-42.9M
$9.8M
$-30.2M
Q2 • 25
$-28.9M
$-151M
$295M
$-28.9M
Q3 • 25
-4.30%
250.99%
2,902.62%
-4.30%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Mineralys Therapeutics, Inc. Common Stock share?
Collapse

Mineralys Therapeutics, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Mineralys Therapeutics, Inc. Common Stock have?
Collapse

Mineralys Therapeutics, Inc. Common Stock currently has 79.1M shares.

Does Mineralys Therapeutics, Inc. Common Stock pay dividends?
Collapse

No, Mineralys Therapeutics, Inc. Common Stock doesn't pay dividends.

What is Mineralys Therapeutics, Inc. Common Stock 52 week high?
Collapse

Mineralys Therapeutics, Inc. Common Stock 52 week high is $47.65.

What is Mineralys Therapeutics, Inc. Common Stock 52 week low?
Collapse

Mineralys Therapeutics, Inc. Common Stock 52 week low is $8.24.

What is the 200-day moving average of Mineralys Therapeutics, Inc. Common Stock?
Collapse

Mineralys Therapeutics, Inc. Common Stock 200-day moving average is $20.34.

Who is Mineralys Therapeutics, Inc. Common Stock CEO?
Collapse

The CEO of Mineralys Therapeutics, Inc. Common Stock is Jon Congleton.

How many employees Mineralys Therapeutics, Inc. Common Stock has?
Collapse

Mineralys Therapeutics, Inc. Common Stock has 51 employees.

What is the market cap of Mineralys Therapeutics, Inc. Common Stock?
Collapse

The market cap of Mineralys Therapeutics, Inc. Common Stock is $3.51B.

What is the P/E of Mineralys Therapeutics, Inc. Common Stock?
Collapse

The current P/E of Mineralys Therapeutics, Inc. Common Stock is null.

What is the EPS of Mineralys Therapeutics, Inc. Common Stock?
Collapse

The EPS of Mineralys Therapeutics, Inc. Common Stock is -$2.92.

What is the PEG Ratio of Mineralys Therapeutics, Inc. Common Stock?
Collapse

The PEG Ratio of Mineralys Therapeutics, Inc. Common Stock is null.

What do analysts say about Mineralys Therapeutics, Inc. Common Stock?
Collapse

According to the analysts Mineralys Therapeutics, Inc. Common Stock is considered a buy.